Summary
Cilta-cel is a type of immunotherapy called CAR T-cell therapy, which is typically administered after immune cells (lymphocytes) are reduced in the body through chemotherapy.
The study is assessing how well cilta-cel works when it's given after two different ways of lowering the immune cells (lymphodepletion): with a combination of chemotherapies (cyclophosphamide and fludarabine) or just one chemotherapy (cyclophosphamide).
You may be eligible if you have newly diagnosed multiple myeloma and have received at least 3 cycles, and no more than 5 cycles, of induciton therapy (DRd, VRd or DVRd).
Participants in the study will be allocated to one of two treatment groups, called Cohorts.
All participants will continue to receive 1-2 more cycles of the induction regimen (DRd, VRd or DVRd) that they were receiving prior to screening for this study.
After the completion of induction therapy, participants will either receive a conditioning regimen of cyclophosphamide (Cohort A) or cyclophosphamide and fludarabine (Cohort B) daily for 3 days as intravenous (IV) infusions, followed by Ciltacel IV infusion on Day 1.
Participants will later enter the post-treatment phase, which will start on Day 113 and last until end of study or cohort completion.